Arovella Therapeutics Limited · ASX:ALA
Arovella Therapeutics — Technical Presentation (April 2023)
28 slides from Arovella Therapeutics's technical presentation, Apr 19, 2023
Slide 1: Arovella AACR Poster Webinar Presentation (ASX Release)
ASX: ALA Arovella Therapeutics Limited ACN 090 987 250 ASX Release For personal use only 19 April 2023 AROVELLA AACR POSTER WEBINAR PRESENTATION • Investor webinar to be held 11AM AEST today • Describing new data presented at AACR Annual Meeting demonstrating that ALA-101 confers significant anti-tu
Slide 2: Notes to Editors: About Arovella Therapeutics
ASX: ALA Arovella Therapeutics Limited ACN 090 987 250 NOTES TO EDITORS: About Arovella Therapeutics Ltd For personal use only Arovella Therapeutics Ltd (ASX: ALA) is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College Londo
Slide 3: ALA-101 Confers Significant Anti-Tumour Effect and Survival Benefit in Aggressive Leukemia Model
For personal use only ASX:ALA ALA-101 Confers Significant Anti-Tumour Effect and Survival Benefit in Aggressive Leukemia Model AACR Poster Presentation Webinar 19 April 2023
Slide 4: Disclaimer
Disclaimer 1. The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Arovella Therapeutics Limited (Company). For pers
Slide 5: New Data Presented at AACR 2023
New Data Presented at AACR 2023 For personal use only Key Highlights: iNKT cells could be well expanded ALA-101 killed tumour cells that express CD19, including primary patient tumour cells ALA-101 significantly extended the lifespan of mice with aggressive human B-Cell Acute Lymphoblastic Leu
Slide 6: New Data Presented at AACR 2023
New Data Presented at AACR 2023 For personal use only Key Highlights: iNKT cells could be well expanded ALA-101 killed tumour cells that express CD19, including primary patient tumour cells ALA-101 significantly The data confirmed that theproposed extended process manufacturing the lifespan of
Slide 7: iNKT Cells are Primed to Kill Cancer
iNKT Cells are Primed to Kill Cancer invariant Natural Killer T (iNKT) cells have For personal use only evolved to target and kill certain cancer cells The invariant T Cell Receptor (iTCR) does not change between people so cells from healthy donors can be used and administered “off- the-shelf”
Slide 8: Introducing ALA-101 (CAR19-iNKT Cells)
Introducing ALA-101 (CAR19-iNKT Cells) Arovella’s lead product is ALA-101, a For personal use only CD19-targeting CAR-iNKT cell therapy CD19-CAR iTCR CD19 is an antigen expressed on normal B cells and malignant B cells of leukemias and lymphomas o CD19-targeting CAR T-cells is a proven therapeut
Slide 9: CAR-iNKT Cell Therapy Production Advantages
CAR-iNKT Cell Therapy Production Advantages Manufacturing For personal use only Collect Healthy Isolate iNKT cells Engineer iNKT cells to Expand to grow billions of Vial and freeze Donor Blood produce a CAR CAR-iNKT cells CAR-iNKT cells Treatment Thaw CAR-iNKT cells Allogeneic Manufacturing Advantag
Slide 10: Arovella's iNKT Cell Platform Has Several Advantages
Arovella’s iNKT Cell Platform Has Several Advantages Uses mature iNKT cells from healthy adult donors and does not require For personal use only ‘reprogramming’ of stem cells High ‘transduction efficiency’, a high percentage of isolated iNKT cells (>60%) become modified to express the CAR Transducti
Slide 11: CAR19-iNKT (ALA-101) Cells Can Be Expanded
CAR19-iNKT (ALA-101) Cells Can Be Expanded Collect Healthy Isolate iNKT cells Engineer iNKT cells to Expand to grow billions of Vial and freeze Donor Blood produce a CAR CAR-iNKT cells CAR-iNKT cells For personal use only 6000 4000 iNKT cells from a healthy donor were modified to produce a Fold Ex
Slide 12: ALA-101 Kills Tumour Cells That Express CD19
ALA-101 Kills Tumour Cells That Express CD19 SEM cells originate from a patient with an aggressive form of B-cell Acute Lymphoblastic For personal use only Leukemia and express CD19, but not CD1d. ALA-101 cells efficiently kill multiple leukemia cells lines, including SEM ALA-101 eradicated >9
Slide 13: ALA-101 is Dual Targeting
ALA-101 is Dual Targeting For personal use only The dual-targeting potential of ALA-101 was confirmed through efficient killing of C1R-CD1d cells and enhanced killing when these cells were loaded with α-GalCer 80 C1R-CD1d α-GalCer pulsed C1R-CD1d 100 NT iNKT cells 60 80 CAR19-iNKT cells (ALA-101)
Slide 14: ALA-101 is Effective in an Aggressive Leukemia Model
ALA-101 is Effective in an Aggressive Leukemia Model For personal use only ALA-101 was tested in mouse model of B-Cell SEM-luc cells ALA-101 0.5x106 i.v Acute Lymphoblastic Leukemia (B-ALL) model 5x106 cells i.v Mice were transplanted with SEM cells originating from a patient with an aggressive
Slide 15: ALA-101 Dramatically Reduced Tumour Burden
ALA-101 Dramatically Reduced Tumour Burden After 26 days, tumour burden in ALA-101-treated mice was ~90% lower than control For personal use only animals Bioluminescent imaging reveals substantially lower tumour burden in ALA-101-treated animals on Day 8 ALA-101 #2 NT iNKT #5 Vehicle #3 1.5×10 1
Slide 16: ALA-101 Significantly Increased Animal Survival
ALA-101 Significantly Increased Animal Survival ALA-101 significantly enhanced the survival of the mice over untreated controls (p<0.005) For personal use only Vehicle NT iNKT Cells ALA-101 100 Probability of Survival 50 ** P<0.005 0 0 4 8 12 16 20 24 28 32 36 40 Days AACR Poster Fig 5(C) 14 © Cop
Slide 17: Expanded iNKT Cells Retain the Ability to Proliferate
Expanded iNKT Cells Retain the Ability to Proliferate For personal use only ALA-101 cells that had been expanded ~5,000 fold were labeled with a fluorescent dye (CTV) With IL-15 Without IL-15 Cells were then exposed to SEM tumour cells that were either positive (CD19+) or negative (CD19-) for CD
Slide 18: ALA-101 Releases Anti-Tumour Cytokines
ALA-101 Releases Anti-Tumour Cytokines When stimulated by tumour cells expressing CD19, ALA-101 cells dramatically up-regulated For personal use only the anti-tumour cytokines Granzyme B, TNF-α and Perforin Granzyme B TNF-α Perforin Unstimulated Stimulated by CD19+ tumour cells AACR Poster Fig 4(A
Slide 19: Summary
Summary Arovella’s proprietary manufacturing process allows for efficient expansion of iNKT For personal use only cells while retaining functionality o Essential to produce multiple doses from a single batch and address the manufacturing costs and logistical challenges of current autologous therap
Slide 20: Full Poster Available Online
Full Poster Available Online For personal use only Click poster image to access https://www.arovella.com/conference-presentations 18
Slide 21: ALA-101 Scale-Up and Preparation for Clinical Material
ALA-101 Scale-Up and Preparation for Clinical Material For personal use only Complete Optimised viral vector to engineer the CAR with regulatory-friendly elements On track Identify high-frequency iNKT cell donors Ongoing H1 2023 Optimise manufacturing process to produce clinical-grade material P
Slide 22: Arovella's Potential Cancer Targets
Arovella’s Potential Cancer Targets CD19-CAR CD19-CAR DKK1-CAR For personal use only ALA-101 ALA-101 + onCARlytics ALA-104 Non-Hodgkin’s Head and Neck Prostate Cancer Brain Triple Negative Pancreatic Lung Cancer Multiple Lymphoma Cancer Metastases Breast Cancer Cancer Myeloma Additional CARs can b
Slide 23: Arovella's Key Milestones Over Months
Arovella’s Key Milestones Over 18 Months Cell Therapy For personal use only Partner Discovery Lead Optimisation IND-Enabling Phase 1 CAR19-iNKT CD19 Expressing Lymphoma (ALA-101) ALA-101 + Solid Tumours onCARlytics Multiple Myeloma TNBC DKK1-CAR-iNKT (ALA-104) NSCLC Pancreatic TNBC – triple negative
Slide 24: The Potential of CAR-iNKT Cells is Untapped
The Potential of CAR-iNKT Cells is Untapped For personal use only 22 © Copyright Arovella Therapeutics Ltd 2023 Companies with T cell, NK cell, or iNKT cell therapy programs. Source: Company analysis based on public information
Slide 25: Recent Cell Therapy Transactions
Recent Cell Therapy Transactions For personal use only Milestones Total deal Date Type of deal Acquirer/Licensee Target/Licensor Stage Upfront ($M) ($M) value Jan-23 Acquisition Phase I $200 $120 $320 Development Oct-22 Phase II $225* undisclosed collaboration Research Sep-22 Preclincal $70 undisclo
Slide 26: Arovella Financial Overview
Arovella Financial Overview Financial Snapshot 45,000,000 $0.11 For personal use only ALA Price and Volume - 12 Months1 ASX CODE ALA 40,000,000 $0.10 Market capitalisation1 $61.2 million 35,000,000 $0.09 Shares on issue 755.5 million 30,000,000 $0.08 52-week low / high $0.020 / $0.105 $0.07 25,000,0
Slide 27: Arovella Has a Strong Leadership Team
Arovella Has a Strong Leadership Team LEADERSHIP For personal use only Dr. Michael Baker Dr. Nicole van der Weerden Dr. Mini Bharathan Dr. Robson Dossa Ana Radeljevic CEO & MANAGING DIRECTOR CHIEF OPERATING OFFICER SENIOR VP DEVELOPMENT & SENIOR DIRECTOR BUSINESS DEVELOPMENT TRANSLATIONAL MEDICINE M
Slide 28: Thank you
Thank you For personal use only Want to hear more? Explanatory Catch-up on our recent Webinar Explanatory Webinar online to hear the full ALA-101 story! EVENT SPEAKERS Dr. Mini Bharathan Dr. Michael Baker SENIOR VP DEVELOPMENT & CEO & MANAGING TRANSLATIONAL MEDICINE DIRECTOR Email: investor@arovella
Arovella Therapeutics — Technical Presentation (April 2023) on 6ix